BUSINESS

Kyowa Kirin/Sandoz’s Rituxan Biosimilar Approved for Chronic Idiopathic Thrombocytopenic Purpura

September 4, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Kyowa Kirin said on September 3 that the biosimilar version of the cancer agent Rituxan (rituximab) from its strategic collaborator Sandoz has received approval in Japan for additional indications of chronic idiopathic thrombocytopenic purpura and as premedication of ibritumomab tiuxetan.…

To read the full story

Kyowa Kirin/Sandoz’s Rituxan Biosimilar Expands Label
November 19, 2020

BUSINESS

Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
Drug Wholesalers Slam “No-Discussion” Decision on FY2027 Off-Year Price Revision
December 25, 2025
JCR Earns Japan Rights to DMD Drug from Italfarmaco
December 25, 2025
Fujifilm Completes Major Biologics CDMO Plant in Toyama, Eyes 2027 Start-Up
December 25, 2025
Alfresa’s Cell Resources Inks Partnership with Korea’s ENCell
December 25, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…